As of July 2024, several ongoing clinical trials are investigating CAR T cell therapy for autoimmune diseases. Here are some key details:

  1. Multiple trials are evaluating anti-CD19 CAR T cells for systemic lupus erythematosus (SLE):
    o Several clinical trials have been registered worldwide and are in the recruiting process, testing both autologous anti-CD19 and anti-BCMA CAR T cells in SLE patients.
  2. Trials for other autoimmune conditions:
    o A clinical trial is in the recruitment phase for antisynthetase syndrome, a form of myopathy.
    o There are ongoing trials for myasthenia gravis using anti-B cell maturation antigen (BCMA) CAR T cells.
  3. Broader autoimmune disease focus:
    o A study at the Mayo Clinic is exploring BAFFR-based CAR T cells for autoimmune rheumatologic disorders, including SLE, rheumatoid arthritis, and ANCA-associated vasculitis.
  4. Growing interest in the field:
    o The number of clinical trials for CAR T cell therapies in autoimmune disorders has increased significantly in the last seven years, reflecting the hope and potential of this approach.
  5. Expanding targets:
    o While most trials focus on targeting CD19 or BCMA on B cells, researchers are also developing chimeric autoantibody receptor T cells to eliminate specific autoantibody-producing B cell clones, as well as regulatory CAR T cells to dampen autoimmune activation.

These trials aim to validate the promising early results seen in individual case reports and small studies, addressing aspects such as efficacy, safety, and long-term outcomes in larger patient populations. The field is rapidly evolving, with new trials likely to emerge as research progresses.


July 2024 Update:
SOME OF ISRAEL’S RENOWNED HOSPITALS ARE SET TO LAUNCH A CAR-T PROGRAM FOR AUTOIMMUNE DISEASES. CONTACT US FOR MORE DETAILS.

Sources:
BMJ Journals
Mayo Clinic
Pubmed
Chinese medical Journal